A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...
6don MSN
Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...
Satoru Osuka, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Neurosurgery, has been awarded a $50,000 seed grant from the Uncle Kory Foundation to support ...
Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...
A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 ...
The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patien ...
A new study from researchers at the University of Manitoba is shedding new light and providing new hope for those living with a rare and fatal brain cancer, the very disease that claimed the life of ...
TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent glioblastoma ...
6d
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback